Central nervous system neurodegeneration and tinnitus: A clinical experience. Part II: Translational neurovascular theory of neurodegenerative CNS disease and tinnitus

International Tinnitus Journal

Volumn 14, Issue 1, 2008, Pages 43-51

  Shulman, Abraham ^a   Goldstein, Barbara ^b   Strashun, Arnold M ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Inflammation; Ischemia; Neurodegeneration; Neuroprotection; Neurovascular theory

Indexed keywords

ALZHEIMER DISEASE; AUDIOLOGY; BRAIN ISCHEMIA; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; INFLAMMATION; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; REVIEW; SENILE DEMENTIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBJECTIVE IDIOPATHIC TINNITUS; THEORY; TINNITUS;

AGE FACTORS; ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN ISCHEMIA; COMORBIDITY; DEMENTIA, VASCULAR; DOMINANCE, CEREBRAL; GENE THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; TAUOPATHIES; TINNITUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 46049118634     PISSN: 09465448     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Shulman A, Goldstein B, Strashun AM. Central nervous system neurodegeneration and tinnitus: A clinical experience. Part 1. Diagnosis. Int Tinnitus J 13(2):118-131, 2007.
2. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28(4):202-208, 2005.
3. Zipp F, Aktas O. The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29(9):518-527, 2006.
4. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8(9):663-672, 2007.
5. Shulman A. A final common pathway for tinnitus - the medial temporal lobe system. Int Tinnitus J 1(1):115-126, 1995.
6. Choi DW. Excitotoxic cell death. J Neurobiol 23:1261-1276, 1992.
7. A-benzodiazepine- chloride receptor-targeted therapy for tinnitus control: Preliminary report. Int Tinnitus J 8(1):30-36, 2002.
8. Stracher A. Calpain inhibitors as neuroprotective agents in neurodegenerative disorders. Int Tinnitus J 3(2):71-76, 2003.
9. Shulman A, Avitable MJ, Goldstein B. Quantitative electroencephalography power analysis in subjective idiopathic tinnitus patients: A clinical paradigm shift in the understanding of tinnitus, an electrophysiological correlate. Int Tinnitus J 12(2):121-131, 2006.
10. Shulman A, Strashun AM, Afriyie M, et al. SPECT imaging of brain and tinnitus - neurootological neurological implications. Int Tinnitus J 1(1):13-29, 1995.
11. Shulman A, Strashun AM, Avitable MJ, et al. Ultra-high frequency acoustic stimulation and tinnitus control - a PET study. Int Tinnitus J 10(2):113-126, 2004.
12. Bailey TL, et al. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26:573-578, 2004.
13. de la Torre JC. Alzheimer's disease is a vasocognopathy: A new term to describe its nature. Neurol Res 26:517-524.
14. Shulman A. Tinnitus neural substrates: An addendum. Int Tinnitus J 11(1):1-3, 2005.
15. Eggermont JJ, Roberts LE. The neuroscience of tinnitus. Trends Neurosci 27(11):676-682, 2004.
16. Shulman A, Goldstein B. Tinnitus dysynchrony theory: A translational concept for diagnosis and treatment. Int Tinnitus J 12(2):115-120, 2006.
17. Shulman A. A final common pathway for tinnitus - update 2008. Anatomical substrates. Presented at the Thirty-fifth Congress of the Neurootological and Equilibriometric Society, Bad Kissingen, Germany, April 10-13, 2008.
18. Thompson RJ, et al. Ischemia opens neuronal gap junction hemichannels. Science 312:924-927, 2006.
19. Esiri MM. The interplay between inflammation and neurodegeneration in CNS disease. J Immunol 184(1-2):4,16, 2007.
20. Perry WH, Gordon S. Macrophages and the nervous system. Int Rev Cytol 125:203-244, 1991.
21. Peterson JW, et al. Transected neuritis, apoptoticneurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400, 2001.
22. Kirino T, et al. Induced tolerance to ischemia in gerbil hippocampal neurons. J Cereb Blood Flow Metab 11:299-307, 1991.
23. Hewlett KA, Corbett D. Delayed minocycline treatment reduces long-term functional benefits and histological injury in a rodent model of focal ischemia. Neuroscience 141(1):27-33, 2006.
24. Babcock AA, et al. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23:7922-7930, 2003.
25. Dirnagl U, et al. Pathobiology of ischemic stroke: An integrated view. Trends Neurosci 22:391-397, 1999.
26. Koistinaho M, Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia-focus on inflammation. Brain Res Rev 48(2):240-250, 2005.
27. Smith KJ. Nitric Oxide and Axonal Pathophysiology. In SG Waxman (ed), Multiple Sclerosis as a Neuronal Disease. New York: Academic Press, 2005:255-273.
28. Diestel A, et al. Activation of microglial poly (ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation. J Exp Med 198:1729-1740, 2003.
29. Spranger M, et al. Glutamate levels in the cerebrospinal fluid predict clinical outcome of bacterial meningitis. Arch Neurol 53:992-996, 1996.
30. Darman J, et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. J Neurosci 24:7566-7575, 2004.
31. Nixon RA. Autophagy in neurodegenerative disease: Friend, foe, or turncoat? Trends Neurosci 29(9):528-535, 2006.
32. Cohen E, et al. Opposing activities protect against age-onset proteotoxicity. Science 313:1604-1610, 2006.
33. Morimoto RI. Stress, aging, and neurodegenerative disease. N Engl J Med 355(21):2254-2255, 2006.
34. Subjective idiopathic tinnitus. A review of clinical experience, 1979-2005. ORL Otorhinolaringol Relat Spec 55:22-33, 2005.
35. Shulman A. Medical Evaluation. In A Shulman, JM Aran, J Tonndorf, H Feldmann, et al. (eds), Tinnitus Diagnosis/Treatment. Philadelphia: Lea & Febiger, 1991:258-259.
36. Sapolsky RM. Stress, the Aging Brain, and the Mechanisms of Neuron Death. Cambridge, MA: MIT Press, 1992.
37. Mild cognitive impairment. Retrieved June 25, 2007, from http://www.mayoclinic.com/health/mild-cognitive-impairment/DS00553
38. Albert SA. Changing the trajectory of cognitive decline? N Engl J Med 357(5):502-503, 2007.
39. Kuljis RO. Minimal cognitive impairment. Retrieved July 28, 2005, from www.emedicine.com
40. Crook T, et al. Age-associated memory impairment. Dev Neuropsychol 2:261-276, 1986.
41. Levy R. Age-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 6(1):63-68, 1994.
42. Jack CR, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52(7):1397-1403, 1999.
43. Koistinaho M, Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia - focus on inflammation. Brain Res Rev 48(2):240-250, 2005.
44. Shulman A. Epidemiology of Tinnitus. In A Shulman, JM Aran, J Tonndorf, H Feldmann, et al. (eds), Tinnitus Diagnosis/Treatment. Philadelphia: Lea & Febiger, 1991:237-247.
45. Shulman A. Neuroprotective drug therapy: Medical and pharmacological treatment. Int Tinnitus J 3(2):77-94, 1997.
46. Sapolsky RM. New gene therapy against acute neurological insults. Nat Rev Neurosci 4(1):61-69, 2003.
47. Camins A, et al. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12(2):135-148, 2006.
48. Daftary A, Shulman A, Strashun AM, Gottshalk C, et al. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J 10(1):17-23, 2004.
49. Yrjanheikki J, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96(23):13496-13500, 1999.
50. Baskaya MK, et al. Protective effect of 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J Neurosurg 85:112-116, 1996.
51. Bannenberg G, et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143:43-52, 2004.
52. Chu LS, Fang SH, Zhou Y, et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacologica Sinica 28(6):763-772, 2007.
53. Panikashvili C, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531, 2001.
54. Marsicano C, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88, 2003.
55. Ashton JC, et al. Cerebral hypoxia - ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in brain. Neurosci Lett 412(2):114-117, 2007.
56. Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 3116:750-754, 2007.